The probiotic market hit $70 billion globally in 2024. Products promise everything from improved digestion to better immunity, clearer skin, and enhanced mood. The claims are broad. The science is specific — and the specificity is exactly the problem with most probiotic marketing.
Whether probiotics work is not a single question. It's dozens of questions, each answered by looking at individual strains against individual outcomes in specific populations.
What Are Probiotics?
Probiotics are live microorganisms that, when consumed in adequate amounts, may confer a health benefit on the host. That definition from the WHO is carefully worded: "live," "adequate amounts," and "may" are all doing important work.
The key genera in the probiotic space are:
- Lactobacillus — most common in fermented dairy; well-studied for digestive function and vaginal health
- Bifidobacterium — found in the large intestine; evidence for IBS, constipation, and immune modulation
- Saccharomyces — a yeast, not a bacterium; best evidence for antibiotic-associated diarrhea and C. difficile
- Bacillus / soil-based organisms (SBOs) — spore-forming bacteria marketed for resilience; less clinical evidence than Lactobacillus/Bifidobacterium
Within each genus are dozens of species, and within each species are dozens of strains. Lactobacillus rhamnosus GG and Lactobacillus rhamnosus from your yogurt are not the same thing. A study finding that L. rhamnosus GG reduces antibiotic-associated diarrhea does not tell you that a random L. rhamnosus product does the same.
Related: Try our Supplement Stack Audit to test this yourself. Also worth reading: Best Probiotics for Men: Strain-Specific Guide and our The Complete Guide to Supplement Tracking.
The Research: What Actually Has Evidence?
Specific Strains With Strong Evidence
The evidence is strongest when you match a specific, well-characterized strain to a specific outcome.
Lactobacillus rhamnosus GG (LGG) is among the most studied probiotic strains in the world. A 2018 Cochrane systematic review covering over 30 randomized controlled trials found that LGG significantly reduced the duration of acute infectious diarrhea in children and adults. It also has robust evidence for reducing antibiotic-associated diarrhea risk by 50-60% when taken alongside antibiotics.
Saccharomyces boulardii — technically a yeast — has particularly strong evidence in the antibiotic context. A 2012 meta-analysis in the American Journal of Gastroenterology covering 31 randomized trials found that S. boulardii reduced antibiotic-associated diarrhea by 53% and showed significant effect against Clostridioides difficile (C. diff) recurrence.
Bifidobacterium longum and certain Bifidobacterium infantis strains have moderate evidence for IBS symptom reduction — bloating, discomfort, and stool consistency — in multiple randomized controlled trials.
IBS: The Most Studied Non-Infectious Use Case
Irritable bowel syndrome research has produced the most probiotic evidence outside of diarrhea contexts. The challenge is that IBS is heterogeneous — different subtypes (IBS-C, IBS-D, IBS-M) respond differently to different strains.
A 2019 meta-analysis in Gut covering 53 randomized trials found that multi-strain probiotics showed modest but consistent benefits for global IBS symptoms versus placebo. The effect size was small to moderate — probiotics are not a cure, but some subsets of patients show meaningful symptom improvement.
The General Wellness Gap
Where the evidence gets thin is the territory most probiotic marketing occupies: general gut health, immune support, skin, mood, and energy for otherwise healthy people with no specific digestive complaint.
A 2019 review in Cell found that probiotic supplementation in healthy adults produced variable microbiome colonization — some individuals showed robust colonization of supplemented strains while others showed minimal to no change. This "resistance" to colonization may explain why probiotic response varies so dramatically between people.
The gut microbiome in healthy adults is often fairly resilient. Supplemented strains may transiently pass through without establishing. The outcomes you'd hope for — better immune function, improved mood — have limited randomized trial evidence in healthy populations.
Pros
- +Strong evidence for specific strains against antibiotic-associated diarrhea (LGG, S. boulardii)
- +Moderate evidence for IBS symptom reduction with multi-strain protocols
- +S. boulardii has meaningful C. difficile prevention data
- +Very safe for healthy adults — adverse events are rare
- +Fermented foods provide real microbial diversity at low cost
- +Bifidobacterium strains show promise for bloating and gut motility
Cons
- -Strain specificity is critical — generic 'probiotic' products often don't match studied strains
- -CFU (colony forming unit) counts are largely marketing — survival to the gut matters more
- -General wellness claims for healthy adults have limited rigorous trial support
- -Individual colonization response varies widely — some people show no uptake
- -Many products have poor viability — live bacteria require appropriate storage
- -Soil-based organism (SBO) products have less clinical evidence than Lactobacillus/Bifidobacterium
How to Actually Know If It Works for YOU
Probiotic response is one of the most variable supplement domains because it depends on your existing microbiome composition — which is highly individual and influenced by diet, medication history, and genetics.
Be the first to try Prova
We're building an app to track whether probiotics actually works. Join the waitlist.
A structured approach to personal probiotic testing:
- Define the outcome you're targeting: General wellness is unmeasurable. Pick a specific outcome — bloating frequency, stool consistency (use the Bristol Stool Scale for objectivity), frequency of digestive discomfort, or antibiotic-associated diarrhea prevention.
- Choose a strain with evidence for that outcome: For antibiotic recovery, use LGG or S. boulardii. For IBS-type bloating, look for products containing B. longum or multi-strain formulations used in the Gut meta-analysis.
- Track daily for 4-8 weeks: Gut symptoms are noisy — they fluctuate with stress, diet, sleep, and dozens of other factors. Daily tracking over 4-8 weeks creates a baseline you can actually compare against.
- Rotate and reassess: If a strain protocol isn't moving your tracked outcome by 8 weeks, it may not be the right match for your microbiome. This is a space where iteration matters.
The honest expectation: if you have no specific digestive complaint, you may notice nothing measurable. If you have identifiable gut symptoms, the right strain may help.
The Bottom Line
Probiotics work — for specific strains against specific outcomes. L. rhamnosus GG and S. boulardii have strong evidence for antibiotic-associated diarrhea. Multi-strain protocols have moderate evidence for IBS symptom reduction. General wellness claims for healthy adults are largely unsupported by rigorous trials.
CFU counts are less important than strain identity and viability. Match the strain to the problem. Track the right outcome. And if your gut is already healthy with no specific complaint, your expectations for dramatic change should be modest.